Filing Flows

Filing Flows › Companies › ImageneBio › Cash flow

ImageneBio cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$9.1M in Q2 2026 · −$52.6M over twelve months

Operating cash flow−$9.1M
Free cash flow−$9.1M

Analysis

In Q2 2026, ImageneBio generated −$9.1M of operating cash flow. That is $2.8M more than in Q2 2025 (−$11.9M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$52.6M; the largest uses were operating cash flow ($52.6M), other investing ($6.6M); besides operations, cash came from other financing ($147M), shares issued ($35K); the cash balance rose by $88.7M.

Operating cash flow was −$9.1M against net income of −$10.2M. The largest differences: stock-based pay +$911K, payables +$409K, prepaid and other assets −$161K.

Free cash flow

ImageneBio: free cash flow by quarterImageneBio: free cash flow by quarter$13.0MQ3 2024−$3.5MQ4 2024−$7.2MQ1 2025−$11.9MQ2 2025−$21.5MQ3 2025−$7.2MQ4 2025−$14.8MQ1 2026−$9.1MQ2 2026
Operating cash flow less capital spending.
ImageneBio: operating cash flow against capital spendingImageneBio: operating cash flow against capital spendingOperating cash flowCapital spending$13.0M$0Q3 2024−$3.5M$0Q4 2024−$7.2M$0Q1 2025−$11.9M$0Q2 2025−$21.5M$0Q3 2025−$7.2M$0Q4 2025−$14.8M$0Q1 2026−$9.1M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$9.1M, Capital spending $0.

Capital allocation, year by year

ImageneBio: where the cash came from (up) and went (down), by fiscal yearImageneBio: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingBuybacksFY2021: Operating cash flow −$60.3MFY2021: Shares issued $132MFY2021: Capital spending −$1.8M$132MFY2021FY2022: Operating cash flow −$74.1MFY2022: Shares issued $1.1MFY2022: Capital spending −$1.4M$1.1MFY2022FY2023: Operating cash flow −$79.7MFY2023: Shares issued $37.6MFY2023: Capital spending −$414KFY2023: Buybacks −$663K$37.6MFY2023FY2024: Operating cash flow −$21.3MFY2024: Net borrowing $7.5MFY2024: Asset sales $972K$8.5MFY2024FY2025: Operating cash flow −$47.8MFY2025: Net borrowing $15.0MFY2025: Shares issued $45K$15.0MFY2025
Over these 5 years operating cash flow totalled −$283M; the largest uses were operating cash flow ($283M) and capital spending ($3.6M). Cash-flow statements as filed.

Where the cash came from and went

ImageneBio: sources (+) and uses (−) of cash, Q2 2026ImageneBio: sources (+) and uses (−) of cash, Q2 2026Other financing$28.0MCash drawn (+) / kept (−)−$18.6MOperating cash flow−$9.1MOther investing−$346K
ImageneBio: sources (+) and uses (−) of cash, TTM to Q2 2026ImageneBio: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$147MCash drawn (+) / kept (−)−$88.7MOperating cash flow−$52.6MOther investing−$6.6MExchange rates$614KShares issued$35K

From profit to cash

ImageneBio: net income to operating cash flow, Q2 2026ImageneBio: net income to operating cash flow, Q2 2026Net income−$10.2MStock-based pay$911KPayables$409KAccrued liabilities−$76KPrepaid and other assets−$161KOperating cash flow−$9.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$9.1M——−$18.6M−$9.1M
Q1 2026−$14.8M—$35K$18.5M−$14.8M
Q4 2025−$7.2M——$8.6M−$7.2M
Q3 2025−$21.5M——−$97.1M−$21.5M
Q2 2025−$11.9M——−$1.1M−$11.9M
Q1 2025−$7.2M—$45K$7.2M−$7.2M
Q4 2024−$3.5M$7.5M—−$3.5M−$3.5M
Q3 2024$13.0M——−$516K$13.0M

ImageneBio: income statement and cash flow

ImageneBio, Q1 2025: revenue $800K. The chart follows the revenue to costs, profit and cash.

ImageneBio: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.